<DOC>
	<DOCNO>NCT00647296</DOCNO>
	<brief_summary>This 2-part study KNS-760704 patient ALS . - Part 1 randomize , placebo-controlled , multi-center study evaluate safety , tolerability , clinical effect oral administration 3 dosage level KNS 760704 vs. placebo 12 week . - Part 2 randomize , double-blind , 2-arm , parallel group , extension study evaluate safety , tolerability , clinical effect oral administration 2 dosage level KNS-760704 76 week .</brief_summary>
	<brief_title>Safety Tolerability Study KNS-760704 Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled study evaluate safety efficacy KNS-760704 compare placebo . The study conduct 2 part . In Part 1 , approximately 80 eligible patient randomize 1 4 treatment group 12 week treatment : placebo ; low-dose ; mid-dose ; high-dose KNS-760704 . Participants meet eligibility requirement enrol approximately 20 center U.S . In addition visit determine eligibility first visit take study drug , participant require make 5 additional research clinic visit Part 1 . Participants complete 12 week Part 1 eligible randomization Part 2 . The duration Part 2 study 76 week . Subjects receive 1 2 active treatment group 72 week ( low-dose high-dose KNS-760704 ) placebo remain 4-week period Part 2 . Participants tell 4 week placebo treatment give . During Part 2 , participant require make 12 research clinic visit , include baseline visit .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Patients diagnosis familial sporadic ALS , define meeting possible , laboratorysupported probable , probable , definite criterion diagnosis ALS accord World Federation Neurology El Escorial criterion Patients ALS symptom onset &lt; 24 month randomization Patients upright VC &gt; 65 % predicted age , height , gender Patients cause neuromuscular weakness ALS exclude Patients without clinical evidence upper motor neuron dysfunction Patients clinically suspect ALS accord World Federation Neurology El Escorial criterion Patients prior exposure KNS760704 R ( + ) enantiomer pramipexole ( i.e. , R ( + ) pramipexole ) Patients take investigational agent ( include lithium ) within 30 day randomization study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>ALS</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Lou Gehrig</keyword>
	<keyword>Lou Gehrig 's</keyword>
	<keyword>Lou Gehrig 's disease</keyword>
	<keyword>Motor Neuron Disease</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>KNS-760704</keyword>
</DOC>